Astrazeneca Canada Inc.
AstraZeneca Canada Inc., a subsidiary of the global biopharmaceutical company AstraZeneca PLC, is headquartered in Canada and operates extensively across the country. Founded in 1999, AstraZeneca has established itself as a leader in the pharmaceutical industry, focusing on innovative medicines in areas such as oncology, cardiovascular, renal, and respiratory diseases. With a commitment to research and development, AstraZeneca Canada is renowned for its unique portfolio of products, including groundbreaking therapies that address unmet medical needs. The company has achieved significant milestones, including advancements in cancer treatment and the development of vaccines. AstraZeneca's strong market position is underscored by its dedication to improving patient outcomes and its contributions to public health, making it a key player in the Canadian healthcare landscape.
DitchCarbon Score
How does Astrazeneca Canada Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Astrazeneca Canada Inc.'s score of 95 is higher than 96% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
AstraZeneca Canada Inc. currently does not report specific carbon emissions data for the most recent year, as no emissions figures are available. The company is a current subsidiary of AstraZeneca PLC, which cascades its climate commitments and emissions data. AstraZeneca PLC has set ambitious climate targets, including commitments to reduce greenhouse gas emissions across its operations. These targets are aligned with the Science Based Targets initiative (SBTi) and include efforts to address Scope 1, 2, and 3 emissions. However, specific reduction targets or achievements for AstraZeneca Canada Inc. have not been disclosed. The company is actively involved in various sustainability initiatives, including participation in the Carbon Disclosure Project (CDP) and the RE100 initiative, which aims for 100% renewable electricity. These initiatives reflect AstraZeneca's commitment to addressing climate change and reducing its overall carbon footprint. As a subsidiary, AstraZeneca Canada Inc. inherits its climate strategies and performance metrics from AstraZeneca PLC, ensuring alignment with the parent company's sustainability goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 298,498,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 322,319,000 | 000,000,000 | 000,000,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Astrazeneca Canada Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
